Metastatic melanoma: Is biochemotherapy the future?

Medical Oncology

Volumn 22, Issue 2, 2005, Pages 101-111

  Alexandrescu, Doru T ^a   Dutcher, Janice P ^a   Wiernik, Peter H ^a  

^a OUR LADY OF MERCY MEDICAL CENTER   (United States)

Author keywords

Biochemotherapy; Metastatic melanoma; Neopterin; Nitric oxide; Sequence of administration; Survival

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; DACARBAZINE; IMMUNOLOGIC AGENT; INTERLEUKIN 2; NEOPTERIN; NITRIC OXIDE; TAMOXIFEN; VINBLASTINE; VINDESINE;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL KILLING; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG EFFICACY; HUMAN; MACROPHAGE ACTIVATION; MELANOMA; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; MELANOMA; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 22344434804     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:22:2:101     Document Type: Review

References (61)

1. Keilholz U, et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998;16:2921-2929.
2. Allen I, et al. Efficacy of interleukin-2 in the treatment of metastatic melanoma-systematic review and meta-analysis. Sel Cancer Ther 1998;1:168-173.
3. Keilholz U, et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997;15:2579-2588.
4. Keilholz U, et al. Dacarbazine, cisplatin and IFN-α2b with or without IL-2 in advanced melanoma: Final analysis of EORTC randomized phase III trial 18951. Proc Am Soc Clin Oncol 2003;22: 708 (abstr 2848).
5. Dorval T, et al. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study. Cancer 1999;85:1060-1066.
6. Ridolfi R, et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alfa-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 2002;20:1600.
7. Del Vecchio M, et al. Multicenter phase III randomized trial of cisplatin, vindesine and dacarbazine (CVD) versus CVD plus subcutaneous (sc) interleukin-2 (IL-2) and interferon-alpha-2b (IFN) in metastatic melanoma patients (pts). Proc Am Soc Clin Oncol 2003;22: 709 (abstr 2849).
8. Atkins MB, et al. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol 2003;22: 708 (abstr 2847).
9. Atzpodien J, et al. Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer 2002;86:179-184.
10. Eton O, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002;20:2045-2052.
11. Rosenberg SA, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999;17:968-975.
12. Legha SS, et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2and interferon-alpha. Ann Oncol 1996;7:827-835.
13. Groenewegen G, Bloem A, De Gast GC. Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha. Cancer Immunol Immunother 2002;51:630-636.
14. Richards JM, et al. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992;10:1338-1343.
15. de Gast GC, et al. Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma. Br J Cancer 2003;88:175-180.
16. Gonzalez Cao M, et al. Biochemotherapy with temozolamide (TMZ) and IL2 subcutaneous (sc) in metastatic melanoma (MM). Proc Am Soc Clin Oncol 2003;22: page 718 (abstr 2888).
17. Richards JM, et al. Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. J Clin Oncol 1999;17:651-657.
18. Vaughan MM, et al. GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanoma. Ann Oncol 2000;11:1183-1189.
19. Thompson JA, et al. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma. Cancer J Sci Am 1997;3 (Suppl 1):S29-34.
20. Khayat D, et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 1993;11:2173-2180.
21. Thomson DB, et al. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res 1993;3:133-138.
22. Antoine EC, et al. Salpetriere Hospital experience with biochemotherapy in metastatic melanoma. Cancer J Sci Am 1997;3(Suppl 1):S16-21.
23. Dillman RO, et al. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11. Cancer Biother Radiopharm 2000;15:487-494.
24. Flaherty LE, et al. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials. J Clin Oncol 2001;19:3194-3202.
25. Kashani-Sabet M, et al. Outpatient combination chemoimmunotherapy for patients with metastatic melanoma. Results of a phase I/II trial. Cancer 1999;86:2160-2165.
26. Vorobiof DA, Bezwoda WR. A randomised trial of vindesine plus interferon-alpha 2b compared with interferon-alpha 2b or vindesine alone in the treatment of advanced malignant melanoma. Eur J Cancer 1994;30A:797-800.
27. Carpano S, et al. Biochemotherapy with carboplatin (CBDCA), dacarbazine (DTIC) and alfa-interferon (IFN) in treatment of metastatic melanoma (MM). Proc Am Soc Clin Oncol 2002; abstr 2785.
28. Atkins MB, et al. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 1994;12:1553-1560.
29. Flaherty LE, et al. A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer 1993;71:3520-3525.
30. Flaherty LE, et al. A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma. Cancer 1990;65:2471-2477.
31. Dummer R, et al. A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring. Cancer 1995;75:1038-1044.
32. Atzpodien J, et al. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer 1995;31A:876-881.
33. Johnston SR, et al. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer 1998;77:1280-1286.
34. Falkson CI, et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998;16:1743-1751.
35. Paciucci PA, Ryder JS, Mandell JP, Morris JC, Holland JF. Interleukin-2 plus chemotherapy for patients with metastatic melanoma. Melanoma Res 2000;10:291-295.
36. Kamanabrou D, et al. Sequential biochemotherapy of INF-α/IL-2, cisplatin (CDDP), dacarbacine (DTIC) and carmustine (BCNU). Result of a monocenter phase II study in 109 Patients with advanced metastatic malignant melanoma (MMM). Proc Am Soc Clin Oncol 1999; abstr 2044.
37. Stoter G, et al. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study. J Clin Oncol 1991;9:1687-1691.
38. Delva R, et al. A phase II study of sub-cutaneous (sc) interferon alpha (IFN) and oral temozolomide (TMZ) combination after chemo-sensibilisation by high doses intravenous (iv) IFN as first-line treatment in patients with metastatic malignant melanoma. Proc Am Soc Clin Oncol 2003;22:718 (abstr 2886).
39. Atkins MB, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res 2002;8:3075-3081.
40. McDermott DF, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. Clin Cancer Res 2000;6:2201-2208.
41. Gibbs P, et al. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma. Melanoma Res 2000;10:171-179.
42. O'Day SJ, et al. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol 1999;17:2752-2761.
43. Proebstle TM, et al. Long-term outcome of treatment with dacarbazine, cisplatin, interferon-alpha and intravenous high dose interleukin-2 in poor risk melanoma patients. Melanoma Res 1998;8:557-563.
44. Chapman PB, et al. Response and survival in melanoma patients treated with biochemotherapy. Proc Am Soc Clin Oncol 2001; abstr 1427.
45. Ready N, et al. Outpatient chemoimmunotherapy (CIT) with temozolomide (TMZ) for metastatic melanoma, BrUOG 69 a phase II trial. Proc Am Soc Clin Oncol 2003;22:717 (abstr 2885).
46. Boasberg PD, et al. Biochemotherapy for metastatic melanoma with limited central nervous system involvement. Oncology 2003;64:328-335.
47. Hauschild A, et al. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer 2001;84:1036-1042.
48. Spieth R, et al. Temozolomide in combination with interferon alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized phase III multicenter study of the Dermatologic Cooperative Oncology Group (DeCOG) Proc Am Soc Clin Oncol 2003;22:718 (abstr 2887).
49. Bajetta E, et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 1994;12:806-811.
50. Danson S. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol 2003;21:2551-2557.
51. Grimm EA, et al. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy. Clin Cancer Res 2000;6:3895-3903.
52. Anderson CM, et al. Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. Melanoma Res 1998;8:149-155.
53. Maragos CM, et al. Nitric oxide/nucleophile complexes inhibit the in vitro proliferation of A375 melanoma cells via nitric oxide release. Cancer Res 1993;53:564-568.
54. Braunschweiger P, et al. Cisplatin and nitric oxide synergistic cytotoxicity in cP resistant human melanoma cells. Proc Annu Meet Am Assoc Cancer Res 1996;37:404.
55. Thomsen LL, et al. Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma. II: Induction of nitric oxide production. Br J Cancer 1992;66:723-727.
56. Rosenberg SA, et al. Regression of established pulmonary metastases and subcutaneous tumor mediatedby the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985;161:1169-1188.
57. Timoshenko AV, et al. Immunotherapy of C3H/HeJ mammary adenocarcinoma with interleukin-2, mistletoe lectin or their combination. effects on tumour growth, capillary leakage and nitric oxide (NO) production. Eur J Cancer 2001;37:1910-1920.
58. Philip T, et al. Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patients. Cancer Treat Rev 1989;16 (Suppl A):91-104.
59. van der Veen RC. Nitric oxide and T helper cell immunity. Int Immunopharmacol 2001;1:1491-1500.
60. Holan V, et al. Nitric oxide as a regulatory and effector molecule in the immune system. Mol Immunol 2002;38:989-995.
61. Yook YH, et al. Nitric oxide induces BNIP3 expression that causes cell death in macrophages. Biochem Biophys Res Commun 2004;321:298-305.